First and Only Targeted Adjuvant Therapy With FDA-Approved Indication Specifically for Patients With gBRCAm, HER2-Negative High-Risk Early Breast CancerFirst and Only PARP Inhibitor to Show Overall Survival Benefit in Early Breast CancerKENILWORTH, N.J. (BUSINESS WIRE) $MRK #MRK AstraZeneca and Merck (NYSE: MRK),.
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two.